Overview

Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)

Status:
Suspended
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
Phase:
Phase 2
Details
Lead Sponsor:
Matthias Griese
Treatments:
Hydroxychloroquine